Expertenstellungnahme zur Substitutionstherapie bei Patienten mit Alpha-1 Antitrypsin-Mangel^[*]

Zusammenfassung

Die Substitutionstherapie bei Alpha-1 Antitrypsin-Mangel soll das Voranschreiten eines Lungenemphysems verzögern, die Exazerbationshäufigkeit reduzieren und die Lebensqualität der Patienten verbessern. Dieses Expertenstatement fasst die wichtigsten Therapiestudien zur Substitutionstherapie bei Patienten mit schwerem Alpha-1 Antitrypsin-Mangel und Lungenemphysem kurz zusammen. Aus den verfügbaren Studienergebnissen werden Indikationen und Kontra­indikationen für eine dauerhafte intravenöse Substitutionstherapie mit humanem Alpha-1 Antitrypsin abgeleitet. Sicherheitsaspekte und die Kontroversen um das Thema werden ausführlich diskutiert.

Abstract

Augmentation therapy in Alpha-1 Antitrypsin Deficiency aims to reduce the progression of lung emphysema, to reduce exacerbation frequency, and to improve quality of life. This expert statement briefly summarizes the most important treatment studies performed in patients with Alpha-1 Antitrypsin Deficiency and severe lung emphysema. Indications and contraindications for long-term intravenous augmentation therapy with human Alpha-1 Antitrypsin are derived from the available study results. Safety issues and the controversies of this topic are discussed in detail.

• Literatur

• 1 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2013 http: //www.goldcopd.org
• 2 Ferrarotti I, Thun GA, Zorzetto M et al. Serum levels and genotype distribution of alpha1-antitrypsin in the general population. Thorax 2012; 67: 669-674
• 3 Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest 1990; 85: 1343-1352
• 4 Stoller JK, Aboussouan LS. Alpha1-Antitrypsin deficiency: intravenous augmentation therapy: current understanding. Thorax 2004; 59: 708-712
• 5 American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med 2003; 168: 818-900
• 6 Vogelmeier C, Buhl R, Criée CP et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 2007; 61: e1-e40
• 7 Schroth S, Koczulla R, Herr C et al. Alpha-1-antitrypsin Magel: Diagnose und Therapie der pulmonalen Erkrankung. Pneumologie 2009; 63: 335-341
• 8 Köhnlein T, Welte T. Alpha-1 Antitrypsin Deficiency: Pathogenesis, clinical presentation, diagnosis, and treatment. Am J Med 2008; 121: 3-9
• 9 Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365: 2225-2236
• 10 Dirksen A, Dijkman JH, Madsen F et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160: 1468-1472
• 11 Dirksen A, Piitulainen E, Parr DG et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33: 1345-1353
• 12 Chapman KR et al. IV Alpha1 Antitrypsin (A1AT) preserves lung density in homozygous Alpha1 Antitrypsin Deficiency (A1ATD); a randomized, placebo-controlled trial. Am J Respir Crit Care Med 2013; 187: A6069
• 13 The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV₁ decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 1998; 158: 49-59
• 14 Seersholm N, Wencker M, Banik N et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV₁ in patients with severe hereditary alpha1-antitrypsin deficiency?. Eur Respir J 1997; 10: 2260-2263
• 15 Chapman KR, Stockley RA, Dawkins C et al. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 2009; 6: 177-184
• 16 Köhnlein T, Janciauskiene S, Welte T. Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency. Ther Adv Respir Dis 2010; 4: 279-287
• 17 Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118: 1480-1485
• 18 Wencker M, Fuhrmann B, Banik N et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001; 119: 737-744
• 19 Meyer FJ, Wencker M, Teschler H et al. Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor. Eur Respir J 1998; 12: 996-997
• 20 Schluchter MD, Stoller JK, Barker AF et al. Feasibility of a Clinical Trial of Augmentation Therapy for alpha(1)-Antitrypsin Deficiency. Am J Respir Crit Care Med 2000; 161: 796-801
• 21 Stockley RA, Parr DG, Piitulainen E et al. Therapeutic efficacy of alpha-1antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010; 11: 136
• 22 Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2010; 7 CD007851